These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 7686469)

  • 21. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
    J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
    Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
    Sharpe M; Easthope SE; Keating GM; Lamb HM
    Drugs; 2002; 62(14):2089-126. PubMed ID: 12269857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
    Faulds D; Balfour JA; Chrisp P; Langtry HD
    Drugs; 1991 Mar; 41(3):400-49. PubMed ID: 1711446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
    Hollingshead LM; Faulds D
    Drugs; 1991 Oct; 42(4):690-719. PubMed ID: 1723369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Epirubicin (4'-epi-adriamycin].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):151-9. PubMed ID: 2404456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
    Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
    Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I-II trial of high-dose epirubicin in patients with lymphoma.
    Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB
    Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.
    Nishio M; Ohata M; Kobayashi H; Suruda T; Uetani K; Funasako M; Nishio K; Sasaki Y; Saijo N
    Jpn J Clin Oncol; 1993 Oct; 23(5):284-90. PubMed ID: 8230753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
    Ganzina F
    Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.